How can today’s CDMOs ensure they can meet tomorrow's demands?

In this interview, Dr. Hans J Johansson discusses the launch of Sunresin’s new Uppsala Centre, chosen for its strong chromatography expertise, strategic location in the EU, and close ties to academia and industry. He outlines the centre’s mission to advance protein purification by developing resins and processes that lower costs and boost productivity, support pharma and start-ups, and accelerate innovation. With recruitment underway and corporate backing for equipment, the new lab marks a fresh era for Sunresin’s European presence.

#chromatography #expertise #expansion #investment #resins #innovation #pharma

0 0

At DCAT Week we sat down with Dennis Angioletti, Group Head of Commercial and Business Development at HAS Group, to discuss the company’s 2025 acquisition of Cerbios and the strategic vision behind it.

0 0

NEW INTERVIEW: Meet Allison Vavala, Senior Director of Business Development at Flamma. She discusses Flamma’s 75th year, the Honkai II expansion, their first FDA inspection in Malvern, and the company’s shift from amino‑acid chemistry to full‑service CMO capabilities in peptides and oligonucleotides.

0 0

Join us for a conversation with Saharsh, Vice Chairman and Managing Director of Neuland. After 18 years with the company, including building its CDMO business, he’s stepping into the CEO role and shares his immediate priorities: closer client–team collaboration, timely delivery of major R&D and facility investments, balancing growth between generic APIs and an expanding CDMO business, and strengthening supply‑chain resilience.

25 0

0 0

We recently spoke with Jagruti Patel from Lonza about a major new facility acquisition and its customer impact. Jagruti explains the Vacaville, CA acquisition, which adds substantial mammalian stainless‑steel capacity, will support US onshoring and dual sourcing, help onboard more customers, and expand Lonza’s end‑to‑end lifecycle and drug‑product offerings.

0 0

Meet Omar Wahab, Head of Fire Processing, Lonza Bioscience. He highlights Lonza’s 30-year cell culture media legacy, the new TheraPEAK platform for AAV/HEK workflows, an FDA-approved cytokine supplement used in 130+ trials.
He also outlines Lonza’s innovation approach: strong internal R&D, partnerships with CDMOs, and recent inorganic growth through the acquisition of Redberry.

Watch the full interview to hear more about these advances and what they mean for the future of cell therapy manufacturing.

0 0

2 0